Related Experiment Video

Updated: Oct 4, 2025

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

2.0K

Immunotherapy for mesothelioma: Moving beyond single immune check point inhibition

Luca Cantini1, Isaac Laniado2, Vivek Murthy2

  • 1Department of Pulmonary Medicine, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Clinical Oncology, Università Politecnica Delle Marche, AOU Ospedali Riuniti Ancona, Italy.

Lung Cancer (Amsterdam, Netherlands)
|February 3, 2022
PubMed

Insights

Immune checkpoint inhibitors (ICIs) show promise for malignant pleural mesothelioma (MPM). Combination therapy (nivolumab plus ipilimumab) is superior to chemotherapy, offering a new first-line treatment strategy for unresectable MPM.

Area of Science:

  • Oncology
  • Immunotherapy
  • Malignant Pleural Mesothelioma Research

Background:

  • Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis.
  • Platinum-based chemotherapy has been the standard treatment for MPM for over a decade.
  • Emerging research explores novel therapeutic strategies, including immunotherapy, to improve outcomes.

Purpose of the Study:

  • To review current and emerging immunotherapy strategies for MPM treatment.
  • To discuss the challenges and advancements in clinical trials for MPM immunotherapy.
  • To highlight the potential of combination immunotherapy in overcoming treatment resistance.

Main Methods:

  • Review of clinical trials and pre-clinical studies on immunotherapy for MPM.
  • Analysis of the efficacy of immune checkpoint inhibitors (ICIs) in MPM treatment.
  • Evaluation of the impact of combination ICI therapy compared to chemotherapy.

Main Results:

  • Single immune checkpoint inhibition results in MPM have been conflicting due to heterogeneity and lack of biomarkers.
  • The Phase III Checkmate743 trial demonstrated superiority of nivolumab plus ipilimumab over chemotherapy in first-line unresectable MPM.
  • This combination therapy received FDA approval, indicating a successful strategy beyond single ICI therapy.

Conclusions:

  • Combination immunotherapy, specifically nivolumab plus ipilimumab, represents a significant advancement in first-line treatment for unresectable MPM.
  • Refining pre-clinical studies with a holistic approach and strengthening multi-institutional collaborations are crucial for future immunotherapy development in MPM.
  • Moving beyond single immune checkpoint inhibition is a promising strategy to improve survival rates in MPM patients.
Keywords:
ChemotherapyCombination therapyImmune check-point inhibitorsImmune-modulationImmunotherapyMalignant pleural mesothelioma

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

761
Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.3K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
711
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
544